Opportunity ID: 237323

General Information

Document Type:: Grants Notice
Funding Opportunity Number:: PAR-13-267
Funding Opportunity Title:: Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01)
Opportunity Category:: Discretionary
Opportunity Category Explanation::
Funding Instrument Type::
Category of Funding Activity:: Health
Category Explanation::
Expected Number of Awards::
Assistance Listings Number(s):: 93.242 — Mental Health Research Grants
Cost Sharing or Matching Requirement:: No
Version:: Synopsis 1
Posted Date:: Jul 08, 2013
Last Updated Date::
Original Closing Date for Applications:: Jan 07, 2016
Current Closing Date for Applications:: Jan 07, 2016
Archive Date:: Feb 07, 2016
Estimated Total Program Funding::
Award Ceiling:: $
Award Floor:: $

Eligibility

Eligible Applicants:: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name:: National Institutes of Health
Description:: The National Institute of Mental Health invites research grant applications to develop innovative programs to advance therapeutics for NeuroAIDS. This Funding Opportunity Announcement (FOA) will support research programs that will advance central nervous system (CNS)-focused therapeutic approaches to: a) address HIV-associated neurocognitive disorders in HIV-infected individuals on highly active anti-retroviral therapy (HAART), b) eradicate persistent HIV-1 from the CNS during chronic infection, c) prevent establishment of HIV-1 in the brain during early infection, and d) assess the potential for CNS toxicity using HAART or candidate drugs that are currently in clinical studies to eradicate HIV-1. Studies to create or adapt existing animal models of HIV-1 infection in the CNS may be proposed to enable assessment of novel HIV CNS-focused therapeutic candidates. Multi-disciplinary, multi-project programs that are focused on improving neurocognition in HIV-infected persons are encouraged. A well defined, synergistic and milestone-driven plan for discovery, preclinical, and/or early clinical hypothesis-driven research should be presented. Public-private partnerships are encouraged but not required.
Link to Additional Information::
Grantor Contact Information:: If you have difficulty accessing the full announcement electronically, please contact:

Version History

Version Modification Description Updated Date
Synopsis 1

Package Status

Below are CLOSED Opportunity Package(s) no longer available for this Funding Opportunity:

Package No: 1

Packages

Assistance Listings Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions Who Can Apply:
93.242 MULTI-PROJECT FORMS-C PKG00181320 Dec 07, 2013 Jan 07, 2016 View eRA Commons Help Desk Organization Applicants